TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05841498

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immunoadsorption
Description: Immunoadsorption (IA) is a well-established extracorporeal therapy for several autoimmune diseases such as systemic lupus. Its therapeutic effect is based on the removal of antibodies (ABs) from the plasma including auto-ABs and it is used if an immediate response to therapy is necessary. Side effects (SE) of the IA are rare, but angiotensin-converting enzyme (ACE)-inhibitors are prohibited concomitant medication. Notable SE may include increased susceptibility to infection, transient disorders of blood coagulation, or allergic reactions to materials of the adsorber or tubing system. To ensure an effective therapy, a blood flow of at least 45 ml/min is necessary. In some patients, adequate blood flow can be achieved by cannulation of peripheral veins but in most patients is the placement of a central venous catheter necessary. Central venous catheter placement carries potential risks such as injury to the lung or mispuncture of the carotid artery.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-apheresis
Description: Sham-apheresis is a procedure without any known therapeutic effects. As there are no known therapeutic effects there are also no known side effects excepted the risk of an allergic reaction to materials of the tubing system or to citrate, which is necessary to prevent clotting inside the extracorporeal system. To ensure a smooth operation a blood-flow of at least 45ml/min is necessary. In some patients, adequate blood flow can be achieved by cannulation of peripheral veins. However, in most patients, placement of a Shaldon catheter into the internal jugular vein is necessary. Shaldon catheter placement carries other potential risks such as injury to the lung resulting in pneumothorax or mispuncture of the carotid artery. However, since the catheter placement is sonography-guided, the risks for such adverse events are minimized.
Study: NCT06313203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Floxuridine
Description: A laparotomy will be performed and a catheter placed in the hepatic artery Connected to a subcutaneous pump. This pump will be percutaneously filled with Floxuridine 6 times in 2 weeks cycles, alternating with heparin-solution. The patients in this arm will also be given GemOX as systemic chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Internal Radiation Therapy (SIRT)
Description: Radioactive Yttrium 90 (Y-90) labeled particles are injected selectively into the feeding arteries of the tumour(s). This allows a high radiation dose in the lesions while limiting systemic side effects.
Study: NCT06247787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and CSF sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Receive IV and IT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Receive IT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imetelstat
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Receive IV or PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study: NCT06362278

Intervention type: OTHER
Intervention: multi-omics studies
Description: 15cc peripheral venous blood will be collected for multi-omics studies, including whole-exome study, transcriptomics \& metabolomics studies.

Intervention type: OTHER
Intervention: multi-omics studies
Description: 15cc peripheral venous blood will be collected for multi-omics studies, including whole-exome study, transcriptomics \& metabolomics studies.

Intervention type: OTHER
Intervention: multi-omics studies
Description: 15cc peripheral venous blood will be collected for multi-omics studies, including whole-exome study, transcriptomics \& metabolomics studies.
Study: NCT06232577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Given by PO
Study: NCT04643899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle Electrostimulation
Description: * Scheduled sessions of 20 minutes per day; 5 days a week~* In physiotherapy or in their room for the most dependent patients~* Installation and monitoring by a physiotherapist or by the trained clinical research nurse~* Modalities:~  * Device program n ° 1: 20mn (2mn of warm-up, 15mn of work at 75hz, then 3mn of recovery)~ * 4 electrodes (2 per thigh): large model (5 \* 10 cm) for better comfort - Dura-Stick Plus model (reference 42200)~ * Gradual auto-increase of the intensity to the highest possible value tolerated, nevertheless allowing a contraction
Study: NCT05386953

Intervention type: DRUG
Intervention: Normal saline
Description: Patients received normal saline as a maintenance crystalloid during liver transplantation surgery.

Intervention type: DRUG
Intervention: Balanced crystalloid solution
Description: Patients received balanced crystalloids such as lactated Ringer's solution or Plasma solution as a maintenance crystalloid during liver transplantation surgery.
Study: NCT04728724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines.
Study: NCT06247787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Receive IT
Study: NCT04722783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Child-Interaction Therapy adapted for children with autism spectrum disorder (PCIT-A)
Description: PCIT is a behavioral family therapy approach emphasizing the integration of traditional child play therapy techniques within a behavioral framework of parent-child therapy and was developed by Eyberg (1988). It is based on attachment theory, social learning theory, and parenting styles theory. Recently, the intervention was adapted to children with ASD by our team (McNeil, Quetsch, \& Anderson, 2019). PCIT-A will last about 8 months, 1 day per week, 60min per day (see Study Protocol, Fig. 2).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Child-Interaction Therapy adapted for children with autism spectrum disorder (PCIT-A)
Description: PCIT is a behavioral family therapy approach emphasizing the integration of traditional child play therapy techniques within a behavioral framework of parent-child therapy and was developed by Eyberg (1988). It is based on attachment theory, social learning theory, and parenting styles theory. Recently, the intervention was adapted to children with ASD by our team (McNeil, Quetsch, \& Anderson, 2019). PCIT-A will last about 8 months, 1 day per week, 60min per day (see Study Protocol, Fig. 2).
Study: NCT05018975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat 800mg BID PO dosing for 15 days
Study: NCT04722783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM) intervention
Description: ESDM intervention provides intensive teaching by trained therapists and parents during natural play and relationship-focused daily routines. It is evidence-based and uses principles of developmental psychology and applied behavior analysis. It was designed for toddlers and preschoolers with autism spectrum disorder by Rogers and Dawson (2010). The first intensive part of ESDM intervention (20h per week) will last 40 weeks of intervention within a period of 12 months. It includes 2 days per week for 6h a day clinic therapy, and 5 days per week for 1h homework tasks, and 2 days per week for 1.5h an early special needs education at home. After the first 12 months, children receive the second lower intensity part of ESDM (7 hours per week). It includes 1 days every two weeks 1h day clinic therapy, and 5 days per week for 1h homework tasks, and 1 days per week for 1.5h an early special needs education at home (see Study Protocol, Fig. 2).
Study: NCT04728724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Non-squamus: Carboplatin AUC 5 + Pemetrexed 500mg/m2; Squamous: Carboplatin AUC 5 + Gemcitabine 1000mg/m2 or Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines.
Study: NCT04722783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM) intervention
Description: ESDM intervention provides intensive teaching by trained therapists and parents during natural play and relationship-focused daily routines. It is evidence-based and uses principles of developmental psychology and applied behavior analysis. It was designed for toddlers and preschoolers with autism spectrum disorder by Rogers and Dawson (2010). The first intensive part of ESDM intervention (20h per week) will last 40 weeks of intervention within a period of 12 months. It includes 2 days per week for 6h a day clinic therapy, and 5 days per week for 1h homework tasks, and 2 days per week for 1.5h an early special needs education at home. After the first 12 months, children receive the second lower intensity part of ESDM (7 hours per week). It includes 1 days every two weeks 1h day clinic therapy, and 5 days per week for 1h homework tasks, and 1 days per week for 1.5h an early special needs education at home (see Study Protocol, Fig. 2).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-hour ESDM
Description: The active control group for PCIT-A stays in the ESDM day clinic therapy for the 12 hours per week while the PCIT-A group will receive 11 hours of ESDM day clinic therapy and 1 hour PCIT-A per week (see Study Protocol, Fig. 2).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early special needs education (ESNE)
Description: The wait-list control group will receive early special needs education. It consists of a 90-minute visit at participants' homes once a week by an employee educated in early special needs education. As soon as space in ESDM is available children will receive the ESDM intervention (stepped-wedge design, see Study Protocol, Fig. 2).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early special needs education (ESNE)
Description: The wait-list control group will receive early special needs education. It consists of a 90-minute visit at participants' homes once a week by an employee educated in early special needs education. As soon as space in ESDM is available children will receive the ESDM intervention (stepped-wedge design, see Study Protocol, Fig. 2).
Study: NCT05382338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT06566014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of XAI-assisted spina bifida diagnosis
Description: AI feedback

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of XAI-assisted spina bifida diagnosis
Description: AI feedback
Study: NCT04242069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy for my Baby
Description: Participants will start the preconception intervention by meeting with a health professional for a motivational interview session on healthy lifestyle habits. Following this interview, participants will have access to a mobile phone application that will allow them to track daily lifestyle modification goals. After a month, they will meet the health professional for a second motivational interview and review their progression. Participants will continue to make lifestyle changes through the preconception period by accomplishing smart goals followed daily in the mobile phone application.~If the woman becomes pregnant, the couple will participate in two more in-person motivational interviews, a month apart. The mobile application will be put in pregnancy mode, and participants will adapt their daily lifestyle goals for the pregnancy. Participants will continue to make lifestyle changes throughout pregnancy by accomplishing smart goals followed daily in the mobile phone application.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants in the control group will receive standard advice on healthy lifestyle habits as provided by their usual care provider. They will receive standard medical care in preconception and pregnancy.~To improve compliance with the study follow-up, participants in this group will have access to a simplified version of the mobile application that contains a fertility calendar and a research visit calendar. This version of the application does not include lifestyle goals or any information on healthy lifestyle habits.
Study: NCT06368817

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT
Study: NCT06322316

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The Ultrasound-guided Retrolaminar Block Group
Description: The ultrasound probe was placed on the back in a transverse orientation on the lateral side of the posterior median line to identify the lamina of the 5th vertebra, ESM, and transversospinalis muscles of the target segment.~A 38-mm 22-gauge regional block needle was advanced using an in-plane technique. When the puncture needle touched the lamina, 20 mL of 0.25% levobupivacaine was administered between the transversospinalis muscle and lamina. The LA diffusion between the lamina and the ESM indicated a successful puncture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The Ultrasound-guided Erector Spinae Plane Block Group
Description: The ultrasound probe was placed on the back in a transverse orientation to identify the tip of the T5 transverse process as flat, squared-off acoustic shadows with a faint image of the pleura visible. When the tip of the transverse process was centered on the ultrasound screen, the probe was rotated to a longitudinal orientation. In the parasagittal view, the following layers were visible superficial to the acoustic shadows of the transverse processes: skin and subcutaneous tissue, trapezius, ESM, and T5 transverse process.~The block needle was inserted in-plane in a cranial-to-caudal direction until contact was made with the T5 transverse process. The correct location of the needle tip in the fascial plane deep to the ESM was confirmed by injecting 0.5-1.0 ml of normal saline and seeing the fluid lifting the ESM off the transverse process without distending the muscle. Then 20 ml levobupivacaine 0.25% was injected.
Study: NCT06295913

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 1, hydroxytyrosol-rich extract capsule (Hytolive®)
Description: Following a two-week washout period, the subjects will receive a bottle containing capsules (Hytolive®) (Group 1). Blood, urine, and fecal samples will be collected from each participant during their stay at the Human Nutrition Unit at the beginning and end of the study. Subjects will be instructed to refrain from consuming products rich in hydroxytyrosol (such as virgin olive oil and olives) and to maintain their usual dietary habits throughout the study. Additionally, olive oil (1L/week) will be provided to each volunteer that will consume during intervention study as the sole source of dietary fat, used for cooking, salad dressing, toasts, etc. in order to control the extra consumption of hydroxytyrosol apart from that provided by the capsule with (Hytolive®).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 2, capsule of placebo
Description: Following a two-week washout period, the subjects will receive a bottle containing capsules (Placebo) (Group 2). Blood, urine, and fecal samples will be collected from each participant during their stay at the Human Nutrition Unit at the beginning and end of the study. Subjects will be instructed to refrain from consuming products rich in hydroxytyrosol (such as virgin olive oil and olives) and to maintain their usual dietary habits throughout the study. Additionally, olive oil (1L/week) will be provided to each volunteer that will consume during intervention study as the sole source of dietary fat, used for cooking, salad dressing, toasts, etc. in order to control the extra consumption of hydroxytyrosol.
Study: NCT06368817

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo second-look surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo second-look surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo second-look surgery
Study: NCT06519136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distance Reiki
Description: According to Usui, the second level Reiki application will be applied for 20 minutes a day between 19.00 and 21.00 in the evening for four consecutive days by the researcher who has completed his second level training, in accordance with the Second Level Reiki Application Protocol.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Reiki
Description: It will be stated that remote energy application will be applied to the Sham Reiki group and no application will be made.
Study: NCT05175014

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV10 full dose
Description: Mass vaccination campaign with one single dose PCV10 vaccine administered as a full dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV10 fractional dose
Description: Mass vaccination campaign with one single dose PCV10 vaccine administered as a fractional dose.
Study: NCT06126497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropanicant
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropanicant
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropanicant
Description: Tablet
Study: NCT04710030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir hydrochloride 500mg caplet
Description: Active Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sugar pill caplet
Description: Placebo Comparator
Study: NCT04411849

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPV Self-Collection
Description: Receive HPV self-testing intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive information about cervical cancer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive information about cervical cancer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation Program
Description: Receive telephone-based patient navigation
Study: NCT05292001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron-Dextran Complex Injection [InFed]
Description: single 1000mg dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Normal saline